摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(3-chloropyridin-4-yl)-6,8-difluoro-7-iodo[1,2,4]triazolo[4,3-a]pyridine | 1057393-81-3

中文名称
——
中文别名
——
英文名称
3-(3-chloropyridin-4-yl)-6,8-difluoro-7-iodo[1,2,4]triazolo[4,3-a]pyridine
英文别名
3-(3-Chloropyridin-4-yl)-6,8-difluoro-7-iodo-[1,2,4]triazolo[4,3-a]pyridine
3-(3-chloropyridin-4-yl)-6,8-difluoro-7-iodo[1,2,4]triazolo[4,3-a]pyridine化学式
CAS
1057393-81-3
化学式
C11H4ClF2IN4
mdl
——
分子量
392.534
InChiKey
WPHAOKJXERIRGQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    19
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    43.1
  • 氢给体数:
    0
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Novel triazolopyridylbenzamides as potent and selective p38α inhibitors
    摘要:
    A new class of p38 alpha inhibitors based on a biaryl-triazolopyridine scaffold was investigated. X-ray crystallographic data of the initial lead compound cocrystallised with p38 alpha was crucial in order to uncover a unique binding mode of the inhibitor to the hinge region via a pair of water molecules. Synthesis and SAR was directed towards the improvement of binding affinity, as well as ADME properties for this new class of p38 alpha inhibitors and ultimately afforded compounds showing good in vivo efficacy. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2012.03.099
  • 作为产物:
    参考文献:
    名称:
    Novel triazolopyridylbenzamides as potent and selective p38α inhibitors
    摘要:
    A new class of p38 alpha inhibitors based on a biaryl-triazolopyridine scaffold was investigated. X-ray crystallographic data of the initial lead compound cocrystallised with p38 alpha was crucial in order to uncover a unique binding mode of the inhibitor to the hinge region via a pair of water molecules. Synthesis and SAR was directed towards the improvement of binding affinity, as well as ADME properties for this new class of p38 alpha inhibitors and ultimately afforded compounds showing good in vivo efficacy. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2012.03.099
点击查看最新优质反应信息

文献信息

  • 3-([1,2,4]TRIAZOLO [4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES
    申请人:Vidal Juan Bernat
    公开号:US20100120731A1
    公开(公告)日:2010-05-13
    New inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) are disclosed herein, as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy.
    本文披露了具有一般式(I)的p38丝裂原活化蛋白激酶的新抑制剂,以及它们的制备过程,包括它们的药物组成物和在治疗中的应用。
  • NEW 3- ([1,2,4] TRIAZOLO [4,3-A] PYRIDIN-7-YL)BENZAMIDE DERIVATIVES
    申请人:Almirall, S.A.
    公开号:EP2118100A1
    公开(公告)日:2009-11-18
  • US8258122B2
    申请人:——
    公开号:US8258122B2
    公开(公告)日:2012-09-04
  • [EN] NEW 3-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DU 3-([1,2, 4] TRIAZOLO [4,3-A] PYRIDIN-7-YL) BENZAMIDE
    申请人:ALMIRALL LAB
    公开号:WO2008107125A1
    公开(公告)日:2008-09-12
    [EN] This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.
    [FR] La présente invention porte sur de nouveaux inhibiteurs de la protéine kinase activée par le mitogène p38 selon la formule générale (I) et sur leurs procédés de préparation, ainsi que sur les compositions pharmaceutiques les incluant et sur leur utilisation dans le cadre d'un traitement.
查看更多

同类化合物

阿扎次黄嘌呤 钠2-氨基-6-甲基-[1,2,4]三唑并[1,5-a]嘧啶-5-醇 苯酚,4-[2-[[7-氨基-2-(2-呋喃基)[1,2,4]三唑并[1,5-a][1,3,5]三嗪-5-基]氨基]乙氧基]- 替格雷洛-d7 替格瑞洛羟基杂质 替格瑞洛杂质R1788033-05-5摩科品牌提供图谱 替格瑞洛杂质K 替格瑞洛杂质J 替格瑞洛杂质H 替格瑞洛杂质F 替格瑞洛杂质85 替格瑞洛杂质27 替格瑞洛杂质 替格瑞洛杂质 替格瑞洛中间体1脱保护杂质 替格瑞洛 曲匹地尔 异亚丙基替卡格雷 布美地尔 唑嘧菌胺 唑嘧磺草胺 吡唑并[1,5-a]嘧啶-7(4H)-酮,2-甲基-6-硝基-,盐钠 去羟基乙氧基替格雷洛 去羟基乙氧基-2,3-O-(二甲基亚甲基)替格雷洛 化合物 T15173 v-三唑并[4,5-d]嘧啶,(3H),3-环戊基-7-偏基硫代- [[[3-(4,7-二氢-7-氧代-1H-1,2,3-三唑并[4,5-d]嘧啶-5-基)-4-丙氧基苯基]氨基]亚甲基]丙二酸二乙酯 [1,2,4]噻唑并[1,5-c]嘧啶-5(6h)-酮 [1,2,4]三氮唑并[1,5-A]嘧啶-2-胺 [1,2,4]三唑并[3,4-f]嘧啶 [1,2,4]三唑并[1,5-a]嘧啶-7-酚,5-壬基- [1,2,4]三唑并[1,5-a]嘧啶-7(1H)-酮,2-甲基-6-硝基-,盐钠 [1,2,4]三唑并[1,5-A]嘧啶-2-羧酸甲酯 [1,2,4]三唑并[1,5-A]嘧啶-2-羧酸 [1,2,4]三唑[1,5,A]嘧啶-7-氨基 [(1R,3S)-3-(5-氨基-7-氯-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)环戊基]甲醇 [(1R,3S)-3-(5,7-二氨基-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)环戊基]甲醇 N-甲基-1H-1,2,3-三唑并[4,5-d]嘧啶-7-胺 N-(4'-氟丁酰苯)-4-(4-氯苯基)吡啶正离子 N-(2,6-二氯苯基)-5,7-二甲基[1,2,4]三唑并[1,5-a]嘧啶-2-磺酰胺 N-(2,6-二氯-3-甲苯基)-5,7-二甲氧基-[1,2,4]三唑[1,5-a]嘧啶-2-磺酰胺 N-(2,6-二氯-3-甲基苯基)-5,7-二氯-1,2,4-三唑并[1,5-a]吡啶-2-磺酰胺 N-(1,5,6,7-四氢-3,6-二甲基-5,7-二氧代-1,2,4-三唑并[4,3-c]嘧啶-8-基)-乙酰胺 EED抑制剂(EEDINHIBITOR-1) 9H-7,8-二氢-(1,2,3)三唑并(4',5'-4,5)嘧啶并(6,1-b)(1,3)噻嗪-5(3H)-酮 9-乙基-2,4,7,8,9-五氮杂双环[4.3.0]壬-1,3,5,7-四烯-3,5-二胺 8-甲氧基-3-甲基-[1,2,4]三唑并[4,3-C]嘧啶 8-甲基-1,3,7,9-四氮杂双环[4.3.0]壬-2,4,6,8-四烯 8-溴-[1,2,4]三唑并[4,3-c]嘧啶 8-溴-5-(甲硫基)[1,2,4]三唑并[4,3-c]嘧啶